Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Ribupatide

A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

Fujian Shengdi Pharmaceutical Co · Phase 3 · Recruiting · Enrollment 675

NCT07670884

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
HRS9531 Tablet Groupn/rn/rn/rn/r
HRS9531 Tablet Placebo Groupn/rn/rn/rn/r

Not shown

  • HRS9531 Tablet Group: endpoint not reported
  • HRS9531 Tablet Placebo Group: endpoint not reported